PURPOSE: The aim of this study was to evaluate the clinicopathological characteristics of uterine leiomyosarcoma (LMS) and possible prognostic factors. MATERIALS AND METHODS: This study included 31 patients with histologically proven LMS at Samsung Medical Center and Ajou University Hospital between 1994 and 2007. The medical records and available histological slides were reviewed retrospectively. RESULTS: The median age was 46 years (range, 32~63). The most common symptom was vaginal bleeding (11 patients, 35.5%). There were 23 patients with stage I, one patient with stage III, seven patients with stage IV disease. The median follow up time was 29 months (range, 1~94). The most common recurrence site was lung (5 case), followed by pelvis and upper abdomen (2 case). Nine patients died of disease with a 5-year overall survival rate of 63%. Early tumor stage and mitotic count were the prognostic factor in univariate analysis (p<0.0001 and p=0.0031, respectively), but early tumor stage only was associated with prognosis in multivariate analysis (p=0.010 vs p=0.143). Adjuvant treatment for early stage disease did not decrease the recurrence rate (p=0.1075), but high mitotic count (15>10HPF) had a trend for disease recurrence in early stage LMS (p=0.0859). CONCLUSION: Mitotic count less than 15/HPF in early stage may be related with longer progression-free interval, but we could not reach the conclusion that adjuvant therapy in early stage LMS be effective.
PURPOSE: The aim of this study was to evaluate the clinicopathological characteristics of uterine leiomyosarcoma (LMS) and possible prognostic factors. MATERIALS AND METHODS: This study included 31 patients with histologically proven LMS at Samsung Medical Center and Ajou University Hospital between 1994 and 2007. The medical records and available histological slides were reviewed retrospectively. RESULTS: The median age was 46 years (range, 32~63). The most common symptom was vaginal bleeding (11 patients, 35.5%). There were 23 patients with stage I, one patient with stage III, seven patients with stage IV disease. The median follow up time was 29 months (range, 1~94). The most common recurrence site was lung (5 case), followed by pelvis and upper abdomen (2 case). Nine patients died of disease with a 5-year overall survival rate of 63%. Early tumor stage and mitotic count were the prognostic factor in univariate analysis (p<0.0001 and p=0.0031, respectively), but early tumor stage only was associated with prognosis in multivariate analysis (p=0.010 vs p=0.143). Adjuvant treatment for early stage disease did not decrease the recurrence rate (p=0.1075), but high mitotic count (15>10HPF) had a trend for disease recurrence in early stage LMS (p=0.0859). CONCLUSION: Mitotic count less than 15/HPF in early stage may be related with longer progression-free interval, but we could not reach the conclusion that adjuvant therapy in early stage LMS be effective.
Authors: A Gadducci; F Landoni; E Sartori; P Zola; T Maggino; A Lissoni; L Bazzurini; R Arisio; C Romagnolo; R Cristofani Journal: Gynecol Oncol Date: 1996-07 Impact factor: 5.482
Authors: K Mayerhofer; A Obermair; G Windbichler; E Petru; A Kaider; L Hefler; K Czerwenka; S Leodolter; C Kainz Journal: Gynecol Oncol Date: 1999-08 Impact factor: 5.482
Authors: Robert L Giuntoli; Daniel S Metzinger; Connie S DiMarco; Stephen S Cha; Jeff A Sloan; Gary L Keeney; Bobbie S Gostout Journal: Gynecol Oncol Date: 2003-06 Impact factor: 5.482
Authors: M Nola; D Babić; J Ilić; M Marusić; B Uzarević; M Petrovecki; A Sabioncello; D Kovac; S Jukić Journal: Cancer Date: 1996-12-15 Impact factor: 6.860
Authors: B A Goff; L W Rice; D Fleischhacker; H G Muntz; S S Falkenberry; N Nikrui; A F Fuller Journal: Gynecol Oncol Date: 1993-07 Impact factor: 5.482
Authors: F J Major; J A Blessing; S G Silverberg; C P Morrow; W T Creasman; J L Currie; E Yordan; M F Brady Journal: Cancer Date: 1993-02-15 Impact factor: 6.860
Authors: R Rothmund; M Huebner; C Joachim; A Hartkopf; T Fehm; M Bamberg; M Wallwiener; S Brucker; F A Taran Journal: Geburtshilfe Frauenheilkd Date: 2011-12 Impact factor: 2.915
Authors: Alessandra Franzetti Pellanda; Berardino De Bari; Elisabeth Deniaud-Alexandre; Marco Krengli; Paul Van Houtte; Antonella Richetti; Salvador Villà; Hadassah Goldberg; Ewa Szutowicz-Zielińska; Michel Bolla; Heidi Rutten; Marc Van Eijkeren; Philip Poortmans; Guido Henke; Yavuz Anacak; Steve Chan; Christine Landmann; Carine Kirkove; Luciano Scandolaro; Jacques Bernier; René-Olivier Mirimanoff; Mahmut Ozsahin Journal: Chin J Cancer Res Date: 2017-12 Impact factor: 5.087